BURLINGTON, N.C. and SAN FRANCISCO, May 7, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Invitae (OTC:NVTAQ), a leading medical ...

The rumors are true: A week after reports first surfaced that Invitae was on the brink of filing for bankruptcy, the genetic testing company has done exactly that. In a release it put out late Tuesday ...

The 2025 guidance anticipates Diagnostics revenue growth of 6.5% to 7.7%, driven equally by organic growth and the annualization of 2024 acquisitions. Biopharma revenue is forecasted to grow 3% to 5%, ...

Chairman and CEO Adam Schechter said that deals may open up as hospital systems grow concerned about Medicaid cuts and the end of Affordable Care Act subsidies.

SAN FRANCISCO & HOUSTON--(BUSINESS WIRE)--Aranscia, a global provider of diagnostics software, services, and testing solutions, and Invitae Corporation, a leading medical genetics company, today ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Invitae rolled up several ...

The “ Molecular Diagnostics Cancer ” Market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive ...

Invitae has collected a de novo clearance from the FDA for a blood test designed to detect hundreds of potential genetic markers to help evaluate whether a person carries an increased risk of ...